96
Participants
Start Date
December 15, 2023
Primary Completion Date
May 1, 2026
Study Completion Date
November 1, 2028
Tiragolumab
600mg IV every 21 days from Cycle 1 Day 1
Atezolizumab
1,200mg IV every 21 days from Cycle 2 Day 1
RECRUITING
Port Macquarie Base Hospital, Port Macquarie
RECRUITING
Coffs Harbour Health Campus, Coffs Harbour
RECRUITING
Border Medical Oncology Research Unit, Albury
RECRUITING
Ramsay Health Care Australia Pty Ltd trading as The Border Cancer Hospital, Albury
RECRUITING
Orange Base Hospital, Orange
RECRUITING
Barwon Health, Geelong
RECRUITING
Bendigo Health, Bendigo
NOT_YET_RECRUITING
Toowoomba Hospital, Toowoomba
NOT_YET_RECRUITING
Rockhampton Hospital, Rockhampton
RECRUITING
Townsville Hospital, Townsville
NOT_YET_RECRUITING
Cairns Hospital, Cairns
RECRUITING
Fiona Stanley Hospital, Perth
RECRUITING
Royal Hobart Hospital, Hobart
Lead Sponsor
Hoffmann-La Roche
INDUSTRY
The George Institute for Global Health, Australia
OTHER
Omico
OTHER